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C9ORF72 TRANSCRIPTION IN A
FRONTOTEMPORAL DEMENTIA CASE WITH TWO
EXPANDED ALLELES
Discovery of intronic hexanucleotide repeat expan-
sions of the C9ORF72 gene in a significant propor-
tion of patients with amyotrophic lateral sclerosis
(ALS) and frontotemporal dementia (FTD)1,2 was
an important step for research into these disorders.
The C9ORF72 genetic variant is more common than
other described mutations, and, unlike patients with
mutations in SOD1, C9ORF72-ALS clinically and
pathologically resembles the more numerous sporadic
form.3 However, progress has been limited by lack of
understanding of the function of the C9ORF72 locus
in health and disease. It is unknown whether the
expansion causes disease by a gain of toxicity, whether
it disrupts expression of the wild-type protein
encoded by the C9ORF72 gene, or some combina-
tion of both mechanisms.1,2,4
Case. Our case is a woman who presented with dete-
riorating handwriting at age 58 years. Later she devel-
oped features of frontal dysfunction and parkinsonism;
she received a formal diagnosis of behavioral-variant
FTD from a consultant neurologist. Two years after
diagnosis, she has not developed motor weakness or
denervation changes on EMG. The patient had a
brother who died of ALS at age 63 years; no other fam-
ily members are known to have had neurologic disease,
although available information is limited. Several rela-
tives died relatively young (,50 years) from non-
neurologic causes, including her parents; she has no
children.
Detection of 2 expanded C9ORF72 alleles. PCR analysis
of genomic DNA extracted from our patient’s venous
blood did not detect a normal-length C9ORF72 allele
(figure, A); similarly, Southern hybridization analysis5
revealed no normal-length C9ORF72 allele in venous
blood or saliva (figure, B). Instead, 2 expanded alleles
were detected of 50 6 5 repeats and .2,000 repeats
(figure, C).
Investigation of C9ORF72 mRNA expression. qRT-
PCR analysis of RNA extracted from venous blood
cells in our patient and several patients with expansions
of .2,000 repeats in 1 C9ORF72 allele and the
absence of expansion (i.e., ,20 repeats) in another
allele revealed similar levels of C9ORF72 mRNA in
all samples (figure, D). Southern hybridization iden-
tified a lymphoblastoid cell line derived from a
C9ORF72-ALS patient with one expanded C9ORF72
allele of similar size (45 6 5 repeats) to the smaller
expansion in our case (figure, E). qRT-PCR of RNA
extracted from this cell line and other lines with expan-
sions of .2,000 repeats in 1 C9ORF72 allele revealed
that C9ORF72 mRNA levels were twice as high in the
line with the smaller expansion (figure, F). Ethics com-
mittee approval and written consent was obtained for all
biosamples.
Discussion and conclusions. Identification of a
patient with 2 expanded C9ORF72 alleles is an impor-
tant step in the study of C9ORF72 disease. Her disease
severity, defined by age at onset and disease duration, is
not remarkably different from other C9ORF72-positive
patients.6 Notably, the length of expansion is different
in her 2 C9ORF72 alleles, which allowed us to explore
the effect of shorter expansions on C9ORF72 mRNA
expression. We and others have shown that the major-
ity of C9ORF72 neurodegeneration patients carry a
repeat expansion of .2,000 repeats,5 although it has
been suggested that more than 301,2 or even as little as
20 to 22 repeats in 1 C9ORF72 allele are pathogenic.7
A recent study has reported hypermethylation of a CpG
island 59 to the repeat sequence, which did not occur in
samples with intermediate-length expansions of up to
43 repeats.8 If this is the mechanism underlying
reduced mRNA expression, then it should not affect
smaller repeat sizes.
Previously published2 and our own data (figure, G)
demonstrate that the level of C9ORF72 mRNA is
reduced in blood cells from patients with long ex-
pansions of .2,000 repeats, suggesting that expres-
sion of RNA from the expanded allele is
compromised. In a lymphoblastoid cell line from a
patient with a short expansion in 1 C9ORF72 allele,
estimated as 45 6 5 repeats by Southern hybridiza-
tion, the level of C9ORF72 mRNA was approxi-
mately double the level in cell lines from patients
with long expansions (figure, F). This suggests that
an allele with a short pathogenic expansion is nor-
mally expressed, but this finding might reflect a
compensatory increase in transcription of the nor-
mal allele. However, since our patient with 2
expansions does not possess a normal allele, such
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Figure C9ORF72 expansion size and C9ORF72 mRNA expression in lymphoblastoid cells and venous blood
(A) Genotyping PCR of a wild-type control and our patient. The shaded lines represent numbers of repeats from 1 to 30. Thus the
upper panel shows a heterozygous control with 2 normal-length alleles of 1 and 4 repeats. No normal-length allele of less than 30
repeats is detected in our patient, as shown in the lower panel. (B, C) Southern hybridization–based detection of the C9ORF72
allele. (B) Analysis of DNA extracted from venous blood of 5 C9ORF72-positive patients and 1 control. The 1.33-kb band
corresponds to an EcoRI/XbaI fragment derived from a nonexpanded locus. This band is present in patients with a single
C9ORF72 expansion (lanes 3–6, 12) and in normal controls without an expansion (lane 2, 22) but is absent in the patient with
2 expanded alleles (lanes 1 and 7,11) in both venous blood (lane 1) and saliva (lane 7). The 1.05-kb band is an internal control to
show that the absence of 1.33-kb band is not due to a low amount ofDNA loaded or its inability to hybridizewith the labeled probe.
(C) A longer gel allows sizing of both the alleles in the patient with 2 expanded alleles in venous blood. Bands are seen at;1.6 kb
and.12 kb, suggesting that 1C9ORF72 allele of the patient carried 506 5 repeats and the other.2,000 repeats. (D) qRT-PCR
for C9ORF72 mRNA in venous blood cells from C9ORF72-positive patients; error bars illustrate 95% confidence intervals.
Concentration is plotted relative to the concentration in the case with 2 expanded alleles (11). (E) Southern hybridization–based
detection of small-size expansion in the C9ORF72 allele. DNA was extracted from venous blood derived from our case with 2
expanded alleles (left lane), a normal control (middle lane), and a patient with expansion in 1C9ORF72 allele of similar length to the
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compensation could not explain why C9ORF72
mRNA expression in her blood cells is equivalent to
patients carrying 1 normal allele (figure, D). Thus we
conclude that the presence of;50 copies of the repeat
does not significantly affect C9ORF72 gene transcrip-
tion or mRNA stability in vivo. If shorter repeats are
indeed pathogenic, our evidence suggests that this is
unlikely to be mediated by haploinsufficiency.
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smaller expansion in our case (right lane). Bands correspond to genomic fragments carrying 506 5 repeats (left lane), 456 5
repeats (right lane, top band), or no repeats (middle lane and right lane, bottom band). (F) qRT-PCR for C9ORF72 mRNA in
lymphoblastoid cells derived from patients carrying 1 C9ORF72 allele with repeat expansion. Levels of C9ORF72mRNA are
approximately double in the patient with a shorter repeat length compared to patients with .2,000 repeats; error bars
illustrate 95% confidence intervals. (G) qRT-PCR forC9ORF72mRNA in venous blood cells fromC9ORF72-positive patients
and age- and sex-matched controls (CTRL). Levels of C9ORF72mRNA are significantly reduced in the patients compared to
controls.
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